Exelon (rivastigmine) capsules and oral solution and patches - all strengths - Novartis Pharmaceuticals UK Ltd - revised SPC

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Section 4.8 Undesirable effects has been updated to include disseminated cutaneous hypersensitivity reactions (frequency not known). Additionally, decreased appetite, urinary incontinence (common), psychomotor hyperactivity (uncommon), erythema, urticaria, vesicles, allergic dermatitis (not known) have been added as additional adverse reactions that have been observed in patients with Alzheimer's dementia using Exelon transdermal patches.   Depression has been removed as an adverse reaction experienced by patients with dementia associated with Parkinson's Disease using Exelon patches.   Please see link to the SPC for full prescribing information
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news